Publicaciones en las que colabora con Juan Clofent Villaplana (20)

2020

  1. Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

    World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85

2019

  1. High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome

    Endoscopy, Vol. 51, Núm. 2, pp. 142-151

2018

  1. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 9, pp. 585-596

2017

  1. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

2016

  1. Colorectal cancer risk factors in patients with serrated polyposis syndrome: A large multicentre study

    Gut, Vol. 65, Núm. 11, pp. 1829-1837

  2. Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients

    BMC Medicine, Vol. 14, Núm. 1

2014

  1. High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

    Clinical Genetics, Vol. 85, Núm. 6, pp. 583-588

  2. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. Genetic susceptibility variants associated with colorectal cancer prognosis

    Carcinogenesis, Vol. 34, Núm. 10, pp. 2286-2291

  2. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. COGENT (COlorectal cancer GENeTics) revisited

    Mutagenesis, Vol. 27, Núm. 2, pp. 143-151

2011

  1. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer

    Gastroenterology, Vol. 140, Núm. 4, pp. 1174-1181

  2. Case-control study for colorectal cancer genetic susceptibility in EPICOLON: Previously identified variants and mucins

    BMC Cancer, Vol. 11

2010

  1. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  2. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype

    Gastroenterology, Vol. 139, Núm. 3

2009

  1. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

    European Journal of Cancer, Vol. 45, Núm. 3, pp. 365-373

2008

  1. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients

    Journal of Medical Genetics, Vol. 45, Núm. 9, pp. 557-563

2006

  1. Diagnostic yield and clinical outcomes after capsule endoscopy in 100 consecutive patients with obscure gastrointestinal bleeding

    European Journal of Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 881-888

  2. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

    Gut, Vol. 55, Núm. 6, pp. 848-855

1996

  1. Biliopancreatic ascariasis: an infrequent disease in our environment

    Gastroenterología y hepatología, Vol. 19, Núm. 4, pp. 210-212